AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03957564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.
Description: Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in 3 time points：Before neoadjuvant chemotherapy, After 2-3 cycles of neoadjuvant chemotherapy, 10 days after operation.
Study NCT03957564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detect the tumor related DNA in pathological tissues after operation.
Description: Detect the tumor related DNA in pathological tissues after operation.
Study NCT03957564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up of DFS and OS in patients with gastric cancer after operation.
Description: Follow-up of DFS and OS in patients with locally advanced or resectable gastric or gastro-oesophageal Junction cancer.
Study NCT02846532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to \<8 kilogram (kg) will receive 2.2 milligram (mg); 8 to \<10 kg will receive 3.2 mg; 10 to\<12 kg will receive 3.4 mg; 12 to \<20 will receive 4.0 mg and 20 to \<30 will receive 5.0 mg.
Study NCT02846532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
Study NCT02829840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle.
Study NCT02829840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Description: Part 2 Phase I Dose Escalation: 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle.
Study NCT02829840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: About 30 days after end-of-study visit, study staff calls participant and asks if they have had any side effects and/or started any new treatment(s).~If disease appears to be responding to study drugs, study staff calls participant every 3-6 months for up to 5 years and asks how they are doing and about any side effects they may be having.
Study NCT01512303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga
Description: SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
Study NCT01512303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
Study NCT04077996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peritonitis treatment placed in APD
Description: Antibiotic treatment of peritontiis placed in bags of Automated peritoneal dialysis.
Study NCT04077996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peritonitis treatment with one exchange in CAPD
Description: Antibiotic treatment of peritontiis placed in one bag of Continuos ambulatory peritoneal dialysis per 6 hours each day.
Study NCT05656677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive parental involvement
Description: One parent watching a procedural painful intervention, two nurses executing facilitated tucking
Study NCT05656677 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Active parental involvement
Description: One parent watching a procedural painful intervention and at the same time executing facilitated tucking
Study NCT04055792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks
Study NCT04105504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Oral glutathione capsule (500 mg), were taken once daily by the subjects.
Study NCT04105504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral capsule were taken once daily by the subjects.
Study NCT00619073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel + aspirin
Description: Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
Study NCT00619073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
Study NCT00619073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
Study NCT00619073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
Study NCT02180360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capoeira training group
Description: Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol.
Study NCT02280018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-49122944, 5 milligram (mg)
Description: Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
Study NCT02280018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
Study NCT03317938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecobionics
Description: Fecobionics is a new device for studying defecation
Study NCT02526459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Birth plan
Description: Patient will receive a birth plan
Study NCT02882633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30ml bolus of bupivacaine
Description: Local anesthetic
Study NCT02745275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led Health Education
Description: Peer-led health education
Study NCT04116385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT04503239 — intervention group
Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM
Study NCT03276000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: office hysteroscopy
Description: A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
Study NCT00820521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active
Study NCT00820521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02517164 — intervention group
Intervention type: OTHER
Intervention: Measurement of serum 25-hydroxyvitamin D
Study NCT02517164 — intervention group
Intervention type: OTHER
Intervention: Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA).
Study NCT04687800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4mg intracanalicular Insert
Description: intracanalicular insert delivery system
Study NCT04687800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durezol 0.05% Ophthalmic Emulsion
Description: Standard therapy, topical steroid drop
Study NCT03263507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline .9%
Study NCT03263507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donidalorsen
Description: Donidalorsen administered subcutaneously
Study NCT01464502 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CRT Implant
Study NCT01464502 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure-wire guided CRT implant
Description: A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
Study NCT04354714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
Study NCT04354714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Screening, Day 2, Day 4, Day 8, Day 15, and Day 29
Study NCT00549367 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition Counselling
Description: Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
Study NCT00874419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg oral, once a day
Study NCT00874419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/carboplatin
Description: gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
Study NCT02105402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMPT
Description: The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
Study NCT01852994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone replacement
Description: Application quarterly of Testosterone Undecylate
Study NCT00438568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: administered intra-nasally twice a day for 16 weeks
Study NCT00438568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered intra-nasally twice a day for 16 weeks
Study NCT00329797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: A single dose of 500 mg of elemental calcium orally each day for 3 years.
Study NCT00329797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: A single dose of 500 mg of elemental calcium orally each day for 3 years.
Study NCT00329797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
Study NCT00329797 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
Study NCT00329797 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
Study NCT01852994 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise training
Description: Aerobic and strength exercise training
Study NCT00329797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH
Description: LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
Study NCT00329797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH
Description: LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
Study NCT00329797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 400 IU (10μg), orally each day for 3 years.
Study NCT00329797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU (10μg), orally each day for 3 years.
Study NCT03791099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: After subgingival ultrasonic scaling is performed, metronidazole in polymer matrix is applied to the selected periodontal pockets.
Study NCT01430052 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Drug: gemcitabine, S-1
Description: Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.
Study NCT01430052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, S-1, radiotherapy
Description: Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
Study NCT01858935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Description: Single IV infusion.
Study NCT01858935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion.
Study NCT00525655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Multimedia Intervention
Description: Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
Study NCT00525655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking 10-15 minutes to complete.
Study NCT04267484 — intervention group
Intervention type: DEVICE
Intervention: GPS and travel diary
Description: WP1: GPS tracker for 2 weeks and a daily diary about activity (travel diary).
Study NCT04267484 — intervention group
Intervention type: OTHER
Intervention: e-decision support platform
Description: WP2 and WP3: An e-decision support platform that will foster shared decision making about options to stay safe at home for the older adult.
Study NCT00666016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRO19622
Description: TRO19622 500 mg once a day before noon meal during 6 weeks
Study NCT01500681 — intervention group
Intervention type: PROCEDURE
Intervention: Plasma exchange (PLEX)
Description: Regular maintenance PLEX courses, typically 3 procedures monthly
Study NCT03985969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elafibranor
Description: Elafibranor 120mg is a coated tablet for oral administration
Study NCT03985969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHRONO-INDOCID
Description: CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
Study NCT01266187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant surgery + FOLFOX + cetuximab
Description: surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
Study NCT01266187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perioperative/Folfox + cetuximab
Description: 12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery~-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab
Study NCT00452361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus+MMF or MPS or AZA+Steroid
Description: Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
Study NCT00452361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid
Description: The maintenance dose of:~1. MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~2. AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~1. continued for the entire 104-week period of randomized therapy~2. subsequently discontinued~3. restarted after discontinuation
Study NCT01670916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: probiotics
Description: Capsule with 1 x 10\*\*9 Lactobacillus rhamnosus GG and 1 x 10\*\*8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
Study NCT03116152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI308
Description: IBI308 200mg Intravenous drip every three weeks；
Study NCT03116152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel/ irinotecan
Description: paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks
Study NCT02202629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing plant based extracts
Description: Intervention involves single exposure, oral consumption of test article following baseline measurements
Study NCT00756262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG or Culturelle
Description: Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10\^10 bacteria
Study NCT00756262 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus GG or Culturelle
Description: Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10\^10 bacteria
Study NCT00473707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active management of the third stage of labor
Description: standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
Study NCT00473707 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Expectant management of the third stage of labor
Description: standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
Study NCT00473707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin and gentle cord traction with fundal massage
Description: standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
Study NCT00473707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
Study NCT00671021 — intervention group
Intervention type: OTHER
Intervention: Platelet aggregation
Description: Platelet aggregation TxA2 formation